COMPANY

Compugen

Keywords: oncology immuno-oncology cancer Ovarian Cancer Lung Cancer Ovarian Cancer Recurrent Colon Cancer Plasma Cell Neoplasm Multiple Myeloma HNSCC Microsatellite Stable Colorectal Carcinoma MSS-CRC Breast Cancer Endometrial Cancer Ovarian Neoplasm Triple Negative Breast Cancer Lung Neoplasm Neoplasm Malignant Colo-rectal Cancer Endometrial Neoplasms Head and Neck Cancer COM701 COM503

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

Jul 21, 2025 Trial start Phase 1/Phase 2: A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer source ↗
Jan 7, 2025 Trial start Phase 1: A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies source ↗
Aug 31, 2020 Trial start Phase 1/Phase 2: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. source ↗
Mar 31, 2020 Trial start Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies source ↗
Sep 6, 2018 Trial start Phase 1: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 1/Phase 2 · A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer · NCT06888921
Nov 22, 2027 (ESTIMATED) · Phase 1 · A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies · NCT06759649

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06888921	A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer	Phase 1/Phase 2	Active, not recruiting	Jul 21, 2025	2027-03 (estimated)
NCT04354246	COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies	Phase 1	Completed	Mar 31, 2020	Apr 1, 2026 (actual)
NCT06759649	A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies	Phase 1	Recruiting	Jan 7, 2025	Nov 22, 2027 (estimated)
NCT03667716	COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1	Completed	Sep 6, 2018	Jan 30, 2024 (actual)
NCT04570839	COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.	Phase 1/Phase 2	Completed	Aug 31, 2020	May 15, 2024 (actual)